Literature DB >> 49801

Thymopoietin and myasthenia gravis: neostigmine-responsive neuromuscular block produced in mice by a synthetic peptide fragment of thymopoietin.

G Goldstein, D H Schlesinger.   

Abstract

Thymopoietin is the thymic hormone responsible for inducing the differentiation of thymocytes. A synthetic peptide corresponding to positions 29-41 of bovine thymopoietin II, which can reproduce this function of the parent molecule in vitro, also caused neostigmine-responsive neuromuscular block in mice similar to that which thymopoietin itself produces, and which resembles the neuromuscular block of myasthenia gravis. This 13 aminoacid sequence must therefore contain the key residues in the thymopoietin molecule responsible for both T-cell differentiation and neuromuscular effects. These data provide further support for the view that myasthenia gravis is a consequence of thymic disease associated with systemic release of thymopoietin, with ensuing neuromuscular block. This evidence supports the empirically proven treatment of myasthenia gravis by early total thymectomy.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 49801     DOI: 10.1016/s0140-6736(75)90966-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

Review 1.  Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators.

Authors:  E L Ochoa; A Chattopadhyay; M G McNamee
Journal:  Cell Mol Neurobiol       Date:  1989-06       Impact factor: 5.046

2.  Chemical synthesis of a hexadecapeptide segment of ubiquitin that activates adenylate cyclase and induces lymphocytes to differentiate.

Authors:  D H Schlesinger; G Goldstein; M P Scheid; M Bitensky
Journal:  Experientia       Date:  1978-06-15

3.  Microenvironments in the normal thymus and the thymus in myasthenia gravis.

Authors:  M Bofill; G Janossy; N Willcox; M Chilosi; L K Trejdosiewicz; J Newsom-Davis
Journal:  Am J Pathol       Date:  1985-06       Impact factor: 4.307

4.  Lymphocyte function in myasthenia gravis.

Authors:  S Kawanami; A Kanaide; Y Itoyama; Y Kuroiwa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-08       Impact factor: 10.154

5.  Cellular aspects of myasthenia gravis.

Authors:  S Berrih-Aknin; S Cohen-Kaminsky; D Neumann; D Safar; B Eymard; C Gaud; P Levasseur; S Fuchs; J F Bach
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

Review 6.  Thymopoietin to thymopentin: experimental studies.

Authors:  G Goldstein; T K Audhya
Journal:  Surv Immunol Res       Date:  1985

Review 7.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.